ArticleJournal of experimental zoology. Part A, Ecological and integrative physiology2025
Developmental Patterns of Hepatic Peroxisome Proliferator-Activated Receptor (PPAR) Expression in Xenopus laevis and Response to Pharmaceutical Agonists During Metamorphic Climax.
Article in Journal of experimental zoology. Part A, Ecological and integrative physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Developmental Patterns of Hepatic Peroxisome Proliferator-Activated Receptor (PPAR) Expression in Xenopus laevis and Response to Pharmaceutical Agonists During Metamorphic Climax.Journal of experimental zoology. Part A, Ecological and integrative physiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Peroxisome proliferator-activated receptors (PPAR) are master transcriptional regulators that maintain metabolic homeostasis in vertebrates. Amphibians are often exposed to endocrine disrupting compounds (EDCs) that could dysregulate lipid metabolism. Larvae of the African clawed frog (Xenopus laevis) are routinely used as a model to study aquatic EDC exposures, but PPAR expression has not been characterized across larval development or metamorphosis in this species. We conducted two experiments to elucidate (a) the expression in late metamorphosis for xPPARα/β/γ subtypes, and (b) the effect of pharmaceutical PPAR agonists (pirinixic acid, bezafibrate, and ciprofibrate) on the expression of xPPARα/β/γ target genes. Additionally, we considered apical endpoints (body mass, body condition [scaled mass index, SMI], and relative liver mass). We hypothesized pharmaceuticals would agonize hepatic xPPARα/β/γ, upregulating expression of downstream target genes and reducing apical endpoints with variation reflective of developmental patterns of nuclear receptor expression. We observed upregulation of xPPARα during late premetamorphosis (NF 51), prometamorphosis (NF 56-57), and metamorphic climax (NF 58-66), which also held for xPPARγ with exception for peak of metamorphic climax (NF 62). For xPPARβ, we only observed upregulation at conclusion of metamorphic climax (NF 66). Agonists did not cause changes in gene expression for xPPARα/β/γ targets, but pirinixic acid exposure decreased female body condition. The dynamic hepatic expression of xPPARα/β/γ during late metamorphosis is presumably necessary to coordinate energy flux and highlights a potential period of susceptibility to PPAR agonism. However, pharmaceuticals identified to interact with xPPARα/β/γ did not elicit a response concordant with PPAR agonism at high doses. These results suggest that X. laevis may not be a sensitive model for studies testing PPAR-mediated effects of xenobiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.